Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Painful GPP flares can occur suddenly, escalate quickly, and may require urgent hospital care leaving people anxious and uncertain about what the future might hold," said Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. "The EFFISAYIL™ 2 results reinforce the potential of spesolimab to prevent GPP flares, giving patients the power to plan their lives, regardless of their disease. We look forward to presenting the data later this year and sharing the findings with regulatory authorities."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
INGELHEIM, Germany -- Businesswire -- EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.[1,2] Safety data were in line with previously conducted clinical trials with spesolimab.
“Painful GPP flares can occur suddenly, escalate quickly, and may require urgent hospital care leaving people anxious and uncertain about what the future might hold,” said Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. “The EFFISAYIL™ 2 results reinforce the potential of spesolimab to prevent GPP flares, giving patients the power to plan their lives, regardless of their disease. We look forward to presenting the data later this year and sharing the findings with regulatory authorities.”
GPP is a rare skin disease, which is distinct from plaque psoriasis.[4] GPP flares greatly affect a person’s quality of life and can lead to serious and life-threatening complications, including heart failure, renal failure, and sepsis.[4]
Spesolimab (marketed as SPEVIGO®) is currently indicated for the treatment of GPP flares in adults.
About spesolimab
Spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP.[4,6,7] Spesolimab has been approved by regulatory authorities in several countries including the US, Japan, Mainland China and the European Union to treat GPP flares in adults.[8,9]
It is the first approved treatment to specifically target the IL-36 pathway for the treatment of GPP flares that has been evaluated in a statistically powered, randomized, placebo-controlled trial. Further spesolimab data is expected later this year, including the final EFFISAYIL™ 2 results investigating prevention of GPP flares. Spesolimab is also under investigation for the treatment of other IL-36 mediated skin diseases.[10]
About the EFFISAYIL™ clinical trial program
The EFFISAYIL™ clinical trial program includes:
· EFFISAYIL™ 1: Treatment with spesolimab demonstrated rapid pustular and skin clearance in patients with GPP flares, sustained over 12 weeks.[3] These results supported the approval of spesolimab (SPEVIGO®) as the first specific treatment for GPP flares in adults in major markets including the US, Japan, Mainland China and the European Union.[8,9] · EFFISAYIL™ 2: A multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating the efficacy and safety of maintenance treatment with subcutaneous (SC) spesolimab for the prevention of GPP flares and sustained control of GPP symptoms in adolescents and adults.[1,2] · EFFISAYIL™ ON: To evaluate the long-term safety and efficacy of Spesolimab in patients with GPP, who have completed previous Spesolimab trials.[5]
Results from the EFFISAYIL™ 2 and EFFISAYIL™ ON trials will be presented later this year.
For the full press release including ‘Notes to Editors’ and references please visit: press release
View source version on businesswire.com: https://www.businesswire.com/news/home/20230129005023/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Boehringer Ingelheim
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 현대자동차그룹, GBC 콘셉트 디자인 조감도 공개 - 뉴스와이어
- 미래를 현실화하는 첨단 기술의 총집합 ‘나노코리아 2024’ 7월 3일부터 킨텍스에서 개최 - 뉴스
- LG CNS, 실시간 다중 통역 솔루션 ‘오렐로’ 출시 - 뉴스와이어
- 대웅제약, 지사제 시장 꽉 잡았다… 스타빅 6개월 연속 처방액 1위 - 뉴스와이어
- KG 모빌리티, 인증중고차 사업 공식 출범 - 뉴스와이어
- 두들린 공동창업자 이태규 CEO·서동민 CTO, 포브스 ‘영향력 있는 아시아 30세 이하 리더 30인’ 선
- 널담, 고단백 저당 스콘과 베이글에 이어 영양강화 신제품 출시 예고 - 뉴스와이어
- 싱가포르항공, 신한카드와 공동으로 더블 마일리지 및 엘리트 골드 티어 매칭 프로모션 진행 -
- 한국 스트리밍 플랫폼 경쟁 본격화… 하쿠나, 스트리머 유치 위해 ‘소통’ 콘텐츠 승부수 - 뉴
- NIQ 코리아, 쑥쑥 커나가는 국내 펫푸드 시장… 연간 판매액 9000억원 돌파 - 뉴스와이어